Starling Oncology
STLN
36 hedge funds and large institutions have $21.2M invested in Starling Oncology in 2023 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 11 increasing their positions, 10 reducing their positions, and 11 closing their positions.
176% more capital invested
Capital invested by funds: $7.66M → $21.2M (+$13.5M)
10% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 10
2.24% more ownership
Funds ownership: 18.47% → 20.71% (+2.2%)
5% less funds holding
Funds holding: 38 → 36 (-2)
18% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JAIC
Josh Arnold Investment Consultant
Edina,
Minnesota
|
+$848K |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
+$453K |
| 3 |
TAS
TIFF Advisory Services
Radnor,
Pennsylvania
|
+$438K |
| 4 |
KLC
Kent Lake Capital
Reno,
Nevada
|
+$190K |
| 5 |
BlackRock
New York
|
+$91.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PM
Prosight Management
Dallas,
Texas
|
-$251K |
| 2 |
Millennium Management
New York
|
-$109K |
| 3 |
SCM
Saba Capital Management
New York
|
-$78.8K |
| 4 |
YIH
Y-Intercept (HK)
Hong Kong
|
-$76.4K |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$50.9K |
STLN Hedge Fund Activity: Q3 2023 in Review
36 of the 6,311 institutional investors tracked by Wall St. Rank reported a position in Starling Oncology (STLN) for Q3 2023, worth a combined $21.2M — up 176% from $7.66M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of STLN and 9 opened new positions — a net loss of 2 holders — while 10 trimmed existing stakes and 11 added.
The largest buyer was Josh Arnold Investment Consultant, adding an estimated $848K. The largest seller was Prosight Management, exiting entirely with an estimated $251K sold.
- 36 institutional investors held Starling Oncology (STLN) as of Q3 2023, down from 38 in Q2 2023.
- Funds reported $21.2M of Starling Oncology stock for Q3 2023, up 176% quarter-over-quarter.
- 9 funds opened new Starling Oncology positions in Q3 2023 and 11 closed out, a net change of -2 holders.
- The largest Starling Oncology buyer in Q3 2023 was Josh Arnold Investment Consultant, an estimated $848K added.
- The largest Starling Oncology seller in Q3 2023 was Prosight Management, an estimated $251K sold.
Based on aggregated 13F filings for Q3 2023.